Journal of Lipid Research · 2012 · 81 citations · 22 references
MedicinePharmacologyPharmacotherapyClinical NutritionPharmacogeneticsPharmacogenomicsAdipose TissueInsulin ResistanceLipid MetabolismLiver DiseaseTriacylglycerol MetabolismTriglyceride MetabolismFat Content MeasurementFree Fatty Acid MetabolismHepatic Steatosis AssessmentHepatic Triglyceride MetabolismLipid Metabolism EffectsLipid Profile ChangesLipid Profile EffectsTriglyceride Metabolism Disorders
Niacin reduces plasma triglycerides, but it may increase free fatty acids and insulin resistance during long-term treatment. We examined the effect of extended-release niacin on liver fat content in Chinese patients with dyslipidemia and whether the common diacylglycerol acyltransferase-2 (DGAT2) polymorphisms influenced this effect. The 39 patients (baseline liver fat content: 12.8 ± 7.6%, triglycerides: 3.30 ± 1.67 mmol/l) were treated with niacin, gradually increasing the dose to 2 g/day for a total of 23 weeks. The liver fat content and visceral/subcutaneous fat was measured before and after treatment. Subjects were genotyped for the DGAT2 rs3060 and rs101899116 polymorphisms. There were significant (P < 0.001) reductions in plasma triglycerides (−34.9 ± 37.6%), liver fat content (−47.2 ± 32.8%), and visceral fat (−6.3 ± 15.8%, P < 0.05) after niacin treatment. Mean body weight decreased by 1.46 ± 2.7% (1.17 ± 2.44 kg, P < 0.001) during the study, but liver fat changes remained significant after adjustment for age, gender, and body weight changes [mean absolute change (95% CI): −6.1% (−8.0, −4.3), P < 0.001]. The DGAT2 variant alleles were associated with a smaller reduction in liver fat content in response to niacin after adjustment for other covariates (P < 0.01). These findings suggest that niacin treatment may reduce liver fat content in Chinese patients with dyslipidemia and that the mechanism may involve inhibition of DGAT2. However, the findings might have been confounded by the small but significant reductions in body weight during the study. Future large randomized controlled trials are needed to verify these findings. Niacin reduces plasma triglycerides, but it may increase free fatty acids and insulin resistance during long-term treatment. We examined the effect of extended-release niacin on liver fat content in Chinese patients with dyslipidemia and whether the common diacylglycerol acyltransferase-2 (DGAT2) polymorphisms influenced this effect. The 39 patients (baseline liver fat content: 12.8 ± 7.6%, triglycerides: 3.30 ± 1.67 mmol/l) were treated with niacin, gradually increasing the dose to 2 g/day for a total of 23 weeks. The liver fat content and visceral/subcutaneous fat was measured before and after treatment. Subjects were genotyped for the DGAT2 rs3060 and rs101899116 polymorphisms. There were significant (P < 0.001) reductions in plasma triglycerides (−34.9 ± 37.6%), liver fat content (−47.2 ± 32.8%), and visceral fat (−6.3 ± 15.8%, P < 0.05) after niacin treatment. Mean body weight decreased by 1.46 ± 2.7% (1.17 ± 2.44 kg, P < 0.001) during the study, but liver fat changes remained significant after adjustment for age, gender, and body weight changes [mean absolute change (95% CI): −6.1% (−8.0, −4.3), P < 0.001]. The DGAT2 variant alleles were associated with a smaller reduction in liver fat content in response to niacin after adjustment for other covariates (P < 0.01). These findings suggest that niacin treatment may reduce liver fat content in Chinese patients with dyslipidemia and that the mechanism may involve inhibition of DGAT2. However, the findings might have been confounded by the small but significant reductions in body weight during the study. Future large randomized controlled trials are needed to verify these findings. Nonalcoholic fatty liver disease (NAFLD) characterized by excessive accumulation of intrahepatic triglycerides is associated with multiple metabolic abnormalities that are important cardiovascular risk factors, including increased plasma triglycerides (TG), obesity, insulin resistance, diabetes, and the metabolic syndrome (1Targher G. Marra F. Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?.Diabetologia. 2008; 51: 1947-1953Crossref PubMed Scopus (317) Google Scholar, 2Gastaldelli A. Kozakova M. Hojlund K. Flyvbjerg A. Favuzzi A. Mitrakou A. Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population.Hepatology. 2009; 49: 1537-1544Crossref PubMed Scopus (302) Google Scholar). Hepatic steatosis, the earliest stage of the disease, arises from an imbalance between hepatic TG acquisition and removal (3Cohen J.C. Horton J.D. Hobbs H.H. Human fatty liver disease: old questions and new insights.Science. 2011; 332: 1519-1523Crossref PubMed Scopus (1572) Google Scholar). Increased supply to the liver of free fatty acids (FFA), the substrates for hepatic TG synthesis, from diet and adipose tissue and through increased de novo lipogenesis, promotes hepatic steatosis (3Cohen J.C. Horton J.D. Hobbs H.H. Human fatty liver disease: old questions and new insights.Science. 2011; 332: 1519-1523Crossref PubMed Scopus (1572) Google Scholar, 4Donnelly K.L. Smith C.I. Schwarzenberg S.J. Jessurun J. Boldt M.D. Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.J. Clin. Invest. 2005; 115: 1343-1351Crossref PubMed Scopus (2408) Google Scholar). Nicotinic acid or niacin, one of the naturally occurring B vitamins (vitamin B3), effectively reduces plasma TG levels. This effect was initially thought to be attributable to its antilipolytic effect in adipose tissue, thereby reducing FFA release from adipocytes and decreasing FFA flux to the liver (5Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.J. Intern. Med. 2005; 258: 94-114Crossref PubMed Scopus (503) Google Scholar, 6Gille A. Bodor E.T. Ahmed K. Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action.Annu. Rev. Pharmacol. Toxicol. 2008; 48: 79-106Crossref PubMed Scopus (236) Google Scholar). However, although niacin initially reduces plasma FFA concentrations, this reduction is actually followed by a rebound within 1 to 9 h postdose, depending on the formulation used, and long-term treatment with niacin is associated with increases in plasma FFA, glucose, and insulin resistance (7Carlson L.A. Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis.Acta Med. Scand. 1962; 172: 641-645Crossref PubMed Scopus (213) Google Scholar, 8Vega G.L. Cater N.B. Meguro S. Grundy S.M. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.Am. J. Cardiol. 2005; 95: 1309-1313Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). These observations suggest that the reduction of the FFA delivery to the liver may not be the main mechanism explaining the consistent and maintained plasma TG-lowering effect of niacin. Recent in vitro and animal studies suggested that the TG-lowering effect of niacin might be mediated by its direct and noncompetitive inhibitory effect on hepatic diacylglycerol acyltransferase-2 (DGAT2), a key enzyme that catalyzes the final step of TG synthesis (9Ganji S.H. Tavintharan S. Zhu D. Xing Y. Kamanna V.S. Kashyap M.L. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.J. Lipid Res. 2004; 45: 1835-1845Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar, 10Le Bloc'h J. Leray V. Chetiveaux M. Freuchet B. Magot T. Krempf M. Nguyen P. Ouguerram K. Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs.J. Pharmacol. Exp. Ther. 2010; 334: 583-589Crossref PubMed Scopus (24) Google Scholar). Inhibition of mouse Dgat2 with antisense oligonucleotides in mice with obesity induced by high-fat diet or leptin-deficiency for 7 weeks was associated with reduced hepatic TG synthesis and increased FFA oxidation in hepatocytes, which resulted in significantly improved hepatic steatosis and reduced plasma TG and FFA levels (11Yu X.X. D. S. S. reduction of DGAT2 hepatic steatosis and in obese 2005; PubMed Scopus Google Scholar). Niacin been in patients with have increased risk of metabolic syndrome and but whether it liver fat content through its inhibitory effect on DGAT2 in is The that the effect of niacin on liver fat content was by that weeks of treatment with niacin effect on liver fat which was measured with or on plasma FFA levels in obese with the of the might have been be small to a and the an to may F. J. S. of and niacin on intrahepatic very lipoprotein and insulin in obese with nonalcoholic fatty liver disease.J. Clin. 2010; 95: PubMed Scopus Google Scholar). the study, examined whether niacin treatment the liver fat content in Chinese patients with been suggested that DGAT2 polymorphisms may the liver fat changes during in patients with fatty liver K. F. J. F. A. The DGAT2 is a for the between fatty liver and insulin resistance in 2009; PubMed Scopus Google this whether the common DGAT2 polymorphisms and the effect of niacin on liver fat were Chinese or from to of with dyslipidemia for or for or TG with or to one of the with obesity to with for or for of or increased risk of cardiovascular were in a were from the in the of a one in the of Subjects were a of coronary or other or within of or or or the with controlled or new were with or were to be on a dose of or for weeks to were not or or of or on other niacin and were the for weeks before and the of the study. were not were in a diet for weight or significant changes in body weight within of The was by the of the Chinese of and was from were treated with niacin in increasing of and for 1 and for and were to with diet and other of during the study. were by weeks and 23 of the and were by during the to effects and to which was by during including body and of body fat an were were for lipid glucose, and other weeks and FFA, and lipoprotein were measured before and after niacin treatment. The liver fat visceral adipose tissue and adipose tissue were measured before and after niacin treatment by and The was a an of and of were A was in the to a within the The body was for and were and the were for and lipid were measured to fat which was the fat in of a of the total and and to the fat content and are the of fat and for was not of the and A liver fat content of was to between patients with and fatty liver J.D. P. Horton J.D. J.C. Grundy S.M. Hobbs H.H. of hepatic steatosis in an in the of 2004; PubMed Scopus Google Scholar). were a to a B. A. G. with of Med. 2011; PubMed Scopus Google Scholar). the visceral fat of the were by the of and by the The were and The were to an for The was and The fat the and a by an on P < for for P < 0.01). The glucose, and were measured by insulin was measured the insulin The was in an and were measured the of were measured a enzyme on the FFA and levels were the and the and were measured by A was from for and for the DGAT2 rs3060 and which were from the to in Chinese K. F. J. F. A. The DGAT2 is a for the between fatty liver and insulin resistance in 2009; PubMed Scopus Google Scholar, S. K. A. K. M. T. M. and studies in the diacylglycerol 2 (DGAT2), a for early obesity on PubMed Scopus (24) Google Scholar). The was the and and the The DGAT2 rs3060 and polymorphisms were in P 0.05) and were in with the of variant alleles of these for for one one of the rs3060 variant but a variant for the the DGAT2 rs3060 was in the the rs3060 is in the and may and the for the an S. K. A. K. M. T. M. and studies in the diacylglycerol 2 (DGAT2), a for early obesity on PubMed Scopus (24) Google Scholar). were before in examined during the were by between liver fat content and total and FFA were by The effect of treatment with niacin on liver fat content was by with after and age, gender, and changes in body weight of with body weight 1 and body weight < 1 were by or in during the the DGAT2 rs3060 were by followed by a with age, gender, and changes in body weight A multiple was to the of liver fat changes during the with age, gender, body weight liver fat and the DGAT2 rs3060 were to be the P was < were the Chinese patients with dyslipidemia in this study, 7 patients of or or other the 39 patients the with diabetes, on ± liver fat content 12.8 ± liver fat content was significantly to total fat P 0.001) but not to the plasma TG or FFA There were significant (P < 0.001) increases in ± and reductions in triglycerides (−34.9 ± 37.6%), liver fat content (−47.2 ± 32.8%), and visceral fat (−6.3 ± with niacin treatment were to have fatty liver fat content after 23 weeks of liver fat content of P < 0.01). The liver enzyme decreased during the before and after treatment with weight ± ± ± ± fat ± ± ± ± ± ± fat ± ± adipose tissue ± ± fat ± ± fat ± ± liver fat content ± ± ± ± ± ± ± ± fatty acids ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± insulin ± ± ± ± ± ± acid ± ± ± ± ± ± ± ± ± ± in a new reductions in plasma free and and levels were in the However, the effects of niacin on and levels were not There were significant increases in plasma FFA ± P < insulin ± P < glucose, and levels during the study, and patients needed increases in The acid was not in this of the body weight decreased by ± 2.7% (1.17 ± 2.44 kg, P < 0.001) during the study, the liver fat changes with niacin treatment remained significant after adjustment for age, gender, and body weight with a absolute change (95% of −6.1% (−8.0, (P < There were significant changes in total body fat and fat reductions in liver fat content and were in with weight 1 in with weight < 1 or weight during the with weight ± the liver fat content was reduced from ± to ± after treatment (P < of with body weight 1 or body weight < 1 ± ± weight ± ± ± ± ± ± fat content ± ± ± ± ± ± ± ± change in body weight ± ± in body ± ± in ± ± in ± ± change in liver fat ± ± in liver fat ± ± in free fatty ± ± in ± ± in ± ± in ± ± in ± ± adipose visceral adipose in a new adipose visceral adipose The variant alleles of the DGAT2 rs3060 or were significantly associated with liver fat content changes in response to niacin treatment after adjustment for other covariates Subjects with of the variant a smaller in liver fat content with with the was between the DGAT2 rs3060 and liver fat content or other or changes in body plasma FFA, or liver enzyme by the DGAT2 rs3060 body weight change in weight in body change in in liver change in liver for in liver for in in free fatty in visceral adipose are (95% in body weight were for body weight age, and in liver fat and other were for the age, gender, and body weight changes during the study. were by P for P for in a new visceral adipose are (95% in body weight were for body weight age, and in liver fat and other were for the age, gender, and body weight changes during the study. were by The that the reductions in liver fat content in the DGAT2 rs3060 may be by the with absolute reductions in liver fat content of These were fatty liver with liver fat content of and body were reduced by kg, kg, and kg, during the study. The to after these from the but the between the remained significant P by that liver fat content P < body weight changes P < the DGAT2 rs3060 P and P were of the absolute liver fat change during the study, and these of the in liver fat changes in response to niacin treatment. been that long-term treatment with niacin is associated with a rebound in plasma FFA levels and insulin resistance, but its effect on liver fat content not been increased FFA flux to the liver is associated with excessive accumulation of TG within hepatocytes, a rebound occurring during niacin treatment might hepatic However, the study, for the that niacin treatment significantly reduced liver fat content in Chinese patients with dyslipidemia and that this effect might be mediated by inhibition of DGAT2 in the fat content is to obesity, and body weight reduction is associated with significant in hepatic steatosis K. M. controlled the effects of weight on nonalcoholic 2010; 51: PubMed Scopus Google Scholar). early that a body weight reduction with diet and increases in activity was associated with a in liver fat content in K. F. J. F. A. The DGAT2 is a for the between fatty liver and insulin resistance in 2009; PubMed Scopus Google Scholar). Niacin not to body weight in randomized controlled trials F. J. S. of and niacin on intrahepatic very lipoprotein and insulin in obese with nonalcoholic fatty liver disease.J. Clin. 2010; 95: PubMed Scopus Google Scholar, A. M. M. G. J. M. M. of extended-release niacin on lipid and in patients with 2009; Full Text Full Text PDF PubMed Scopus Google but in the study, was a small but significant reduction in body which is to be to changes in in in the The liver fat content was reduced by during the study, which is that in the study, and this change remained significant after adjustment for body weight There were significant increases in plasma FFA and insulin a significant effect weight reduction is associated with decreases in FFA and insulin levels. The change in FFA levels during niacin treatment was to the change in insulin P < The effect of niacin on liver fat which was examined in a small randomized controlled in obese with that niacin treatment 2 effect on liver fat content in with on F. J. S. of and niacin on intrahepatic very lipoprotein and insulin in obese with nonalcoholic fatty liver disease.J. Clin. 2010; 95: PubMed Scopus Google Scholar). The between the studies may be to the The was in obese body with liver fat content: plasma TG of < TG was in Chinese patients were obese body but plasma TG levels The of fat accumulation in the liver between the studies to the These suggest that niacin might reduce liver fat content in with plasma TG levels but not in with other for obesity or the small reduction in body weight may to liver fat reduction in study, the liver fat content was reduced by P < in the an increase in body The DGAT2 enzyme catalyzes the final step of in which fatty and diacylglycerol to of hepatic DGAT2 significant hepatic steatosis by increased hepatic TG levels but not insulin resistance in mice M. S. of hepatic steatosis and insulin resistance in mice in the Full Text Full Text PDF PubMed Scopus Google inhibition of Dgat2 with an antisense in obese mice resulted in reduction in hepatic TG plasma and FFA levels (11Yu X.X. D. S. S. reduction of DGAT2 hepatic steatosis and in obese 2005; PubMed Scopus Google Scholar). vitro and animal studies suggested that of DGAT2 may be in the hepatic fat accumulation induced by T. and mechanism of DGAT2 in the of fatty liver disease.J. Lipid Res. 2010; 51: Full Text Full Text PDF PubMed Scopus Google Scholar). Niacin was to and noncompetitively the activity of DGAT2 in (9Ganji S.H. Tavintharan S. Zhu D. Xing Y. Kamanna V.S. Kashyap M.L. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.J. Lipid Res. 2004; 45: 1835-1845Abstract Full Text Full Text PDF PubMed Scopus (191) Google and is the to a significant between the DGAT2 and the liver fat changes in response to niacin treatment in patients with The of the that DGAT2 may a in the pharmacological effect of niacin. There was significant in plasma TG the DGAT2 although with variant alleles to have a smaller reduction in plasma TG levels. the DGAT2 is S.J. S. and Lipid Res. 2008; 49: Full Text Full Text PDF PubMed Scopus Google Scholar). have been in the the and in the in but the of these polymorphisms in the DGAT2 have not been or S. K. A. K. M. T. M. and studies in the diacylglycerol 2 (DGAT2), a for early obesity on PubMed Scopus (24) Google Scholar). of these are in Chinese This the common polymorphisms in rs3060 and which are the and in not significantly liver fat changes during in a in patients with fatty liver K. F. J. F. A. The DGAT2 is a for the between fatty liver and insulin resistance in 2009; PubMed Scopus Google the that the variant alleles of the DGAT2 rs3060 or were associated with smaller liver fat changes in response to niacin these polymorphisms might be to effects and the of niacin. A in in which the DGAT2 is to the of that an in the of DGAT2 was significantly associated with and this may that polymorphisms in the of DGAT2 the of the B. B. and with of the and DGAT2 2011; of 2011; Scholar). The DGAT2 polymorphisms were not associated with obesity or body weight changes during the study, in studies K. F. J. F. A. The DGAT2 is a for the between fatty liver and insulin resistance in 2009; PubMed Scopus Google Scholar, S. K. A. K. M. T. M. and studies in the diacylglycerol 2 (DGAT2), a for early obesity on PubMed Scopus (24) Google studies suggested that inhibition of Dgat2 with antisense a reduction in liver fat and plasma TG and FFA levels (11Yu X.X. D. S. S. reduction of DGAT2 hepatic steatosis and in obese 2005; PubMed Scopus Google Scholar, K. L. S. J. X.X. S. synthesis hepatic steatosis but liver and in obese mice with nonalcoholic 45: PubMed Scopus Google Scholar). the study, the plasma FFA levels h after were although the plasma FFA levels within h after might be reduced in an early metabolic G.L. Cater N.B. Meguro S. Grundy S.M. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.Am. J. Cardiol. 2005; 95: 1309-1313Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). The mechanism of FFA rebound with niacin treatment but a that the FFA rebound after h niacin in was associated with changes in in including a significant reduction in of which increase levels and and reductions in the of key of TG synthesis, and A. S. nicotinic acid in FFA rebound and insulin resistance by and in adipose J. 2011; PubMed Scopus Google Scholar). These changes in in adipocytes may to the increase in in adipocytes and FFA which may be for the of insulin resistance during long-term treatment with niacin A. S. nicotinic acid in FFA rebound and insulin resistance by and in adipose J. 2011; PubMed Scopus Google Scholar, of nicotinic acid on mechanisms and for and effects of the Clin. 2011; PubMed Scopus Google Scholar). This that long-term niacin treatment improved hepatic steatosis, but whether this effect is is that hepatic TG accumulation not insulin resistance or in the although it may not be the fatty acid may a in hepatic and the of nonalcoholic Hepatic and the of nonalcoholic the of fatty acid 2010; PubMed Scopus Google Scholar). in animal of that inhibition of DGAT2 with antisense oligonucleotides improved liver fat content in obese mice but liver and K. L. S. J. X.X. S. synthesis hepatic steatosis but liver and in obese mice with nonalcoholic 45: PubMed Scopus Google which is to increased hepatic FFA levels to of fatty acid that increased hepatic and liver K. L. S. J. X.X. S. synthesis hepatic steatosis but liver and in obese mice with nonalcoholic 45: PubMed Scopus Google Scholar, Hepatic synthesis and nonalcoholic fatty liver 2008; PubMed Scopus Google Scholar). in in its been to be associated with J.D. S. A of the and effects of niacin in PubMed Scopus Google Scholar). the study, niacin reduced liver fat content and increased plasma FFA levels h after which might be associated with increased hepatic FFA levels and increased hepatic However, in liver including and were during the study, and these may be associated with liver fat reduction in the study. This that treatment with niacin significantly improved multiple atherogenic lipid in Chinese patients with dyslipidemia (5Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.J. Intern. Med. 2005; 258: 94-114Crossref PubMed Scopus (503) Google Scholar). However, the and levels were during the study. that the and to be to TG levels in this of patients with P < and P < with with TG levels a smaller reduction or an increase in in response to niacin. Increased by reductions in TG been with treatment of of or in patients with fatty acids and J. Clin. PubMed Scopus Google Scholar, J. S. S.M. Y. S.H. to patients with and low randomized of and niacin 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). These observations may be to increased of very lipoprotein of and which were thought to be atherogenic or of the and increased oxidation of P. of on plasma and to J. Clin. PubMed Scopus Google Scholar, and cardiovascular disease: and J. Clin. PubMed Google Scholar). the mechanism for the between response to niacin and TG levels is it may be to the between and synthesis and this is the to that niacin may reduce plasma and hepatic TG levels in Chinese patients with dyslipidemia have an increased risk of The was by the and and to liver fat content and by during the study. This is its However, a randomized controlled may not be with niacin treatment to the common effect of induced by the drug. The small but significant reduction in the body weight during the may the of the study. This and the it to the effect of niacin on the liver fat liver fat content is very to small changes in Future large randomized controlled trials are needed to verify the effect of niacin on liver fat whether the rs3060 in DGAT2 examined in the the of the and to be this measured the plasma FFA h after but not the effect of niacin on FFA although metabolic with niacin for in with metabolic syndrome may a to changes in FFA after the dose G.L. Cater N.B. Meguro S. Grundy S.M. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.Am. J. Cardiol. 2005; 95: 1309-1313Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). The response may to a of the effect of niacin on but this was not in the study. this suggested that niacin reduced liver fat content in Chinese patients with dyslipidemia and that the common polymorphisms in DGAT2 might the hepatic TG response to this may be significantly confounded by the body weight changes during the study. Future large randomized studies are to or this and to the of this hepatic TG reduction on in patients with The increases in FFA and insulin levels during long-term treatment of niacin may of the effects on cardiovascular The patients for and the other of the to this for in and of patients and for in diacylglycerol acyltransferase-2 extended-release nonalcoholic fatty liver disease adipose tissue visceral adipose tissue
22
Kerry L. Donnelly, Coleman I. Smith, Sarah Jane Schwarzenberg et al. · Journal of Clinical Investigation · 2005 · 3.5K citations · Full text